Invivyd, Inc. (IVVD)

NGM – Цена в реальном времени. Валюта: USD

1.49

-0.02 (-1.32%)

При закрытии: May 12, 2026, 4:00 PM EDT

1.46

-0.03 (-1.69%)

До открытия: May 13, 2026, 7:59 AM EDT

11.05.2026

Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination

Invivyd authors evaluated early side effects of prior low-dose investigational monoclonal antibody adintrevimab from the EVADE study, demonstrating minimal tolerability issues Results allow for comparison to contemporary COVID-19 mRNA and protein vaccine tolerability, as well as epidemiologic extrapolation of systemic symptom days experienced via each approach Upcoming LIBERTY trial head-to-head study comparing safety and tolerability between VYD2311 and mRNA vaccine will build on these results in a rigorous, prospective fashion NEW HAVEN, Conn., May 11, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that a preprint of original research regarding COVID monoclonal antibody and vaccine systemic reactogenicity is now available on MedRxiv and is titled “Safety first: should the high tolerability of intramuscular anti-spike COVID-19 monoclonal antibody change our expectations of vaccine safety?

07.05.2026

Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026

NEW HAVEN, Conn., May 07, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 14, 2026 at 8:30 a.m. ET to discuss its first quarter 2026 financial results and provide a corporate update.

05.05.2026

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on May 1, 2026, Invivyd granted 17 newly hired non-executive employees options to purchase an aggregate of 731,000 shares of its common stock, each as a material inducement for each employee's entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.

20.04.2026

Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

Elia to speak at the premier gathering of policy makers, industry leaders, and health experts between 11:30 AM ET – 12:00 PM ET on April 21 Event to be live streamed between 9:00 AM – 1:00 PM ET NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc Elia, Chairman of the Invivyd Board of Directors, is a featured speaker at the POLITICO Health Care Summit on Tuesday, April 21.

09.04.2026

Invivyd, Inc. (IVVD) Discusses Progress in REVOLUTION Clinical Program and Advancement of Measles Monoclonal Antibody Candidate Transcript

09.04.2026

Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program

The company said its Phase 3 DECLARATION trial evaluating VYD2311 for COVID-19 prevention has reached a key interim milestone.

09.04.2026

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

NEW HAVEN, Conn., April 09, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced progress in its REVOLUTION clinical program for VYD2311, a novel monoclonal antibody investigational candidate for the prevention of symptomatic COVID-19. Invivyd also announced today the discovery and advancement of a novel, potentially first- and best-in-class measles monoclonal antibody candidate for treatment and prevention of measles discovered using Invivyd's proprietary technology.

Видео

No Data

There is no data to display

Пресс-релизы

11.05.2026

Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination

05.05.2026

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

20.04.2026

Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

09.04.2026

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Invivyd, Inc. (IVVD)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Invivyd, Inc. (IVVD)

Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination

Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

Invivyd, Inc. (IVVD) Discusses Progress in REVOLUTION Clinical Program and Advancement of Measles Monoclonal Antibody Candidate Transcript

Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Видео

No Data

Пресс-релизы

Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination

Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

Invivyd, Inc. (IVVD) Discusses Progress in REVOLUTION Clinical Program and Advancement of Measles Monoclonal Antibody Candidate Transcript

Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Видео

No Data

Пресс-релизы

Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Search stocks

Invivyd, Inc. (IVVD)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Invivyd, Inc. (IVVD)

Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination

Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

Invivyd, Inc. (IVVD) Discusses Progress in REVOLUTION Clinical Program and Advancement of Measles Monoclonal Antibody Candidate Transcript

Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Видео

No Data

Пресс-релизы

Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination

Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

Invivyd, Inc. (IVVD) Discusses Progress in REVOLUTION Clinical Program and Advancement of Measles Monoclonal Antibody Candidate Transcript

Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Видео

No Data

Пресс-релизы

Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles